Russell Investments Group Ltd. lowered its position in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 59.2% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 76,327 shares of the life sciences company’s stock after selling 110,550 shares during the quarter. Russell Investments Group Ltd. owned about 0.09% of Integra Lifesciences worth $4,261,000 as of its most recent filing with the SEC.
Several other large investors have also recently modified their holdings of IART. Steward Partners Investment Advisory LLC purchased a new stake in shares of Integra Lifesciences during the 2nd quarter worth about $26,000. BNP Paribas Arbitrage SA lifted its position in Integra Lifesciences by 120.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,320 shares of the life sciences company’s stock worth $129,000 after acquiring an additional 1,266 shares in the last quarter. Stanley Laman Group Ltd. acquired a new position in Integra Lifesciences during the 1st quarter worth approximately $223,000. Zions Bancorporation N.A. acquired a new position in Integra Lifesciences during the 1st quarter worth approximately $229,000. Finally, Burney Co. acquired a new position in Integra Lifesciences during the 1st quarter worth approximately $246,000. Institutional investors and hedge funds own 81.91% of the company’s stock.
In other Integra Lifesciences news, major shareholder Richard E. Caruso sold 80,000 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $61.77, for a total value of $4,941,600.00. Following the transaction, the insider now directly owns 134,134 shares of the company’s stock, valued at approximately $8,285,457.18. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Glenn Coleman sold 3,650 shares of the company’s stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $55.00, for a total value of $200,750.00. Following the completion of the transaction, the chief operating officer now directly owns 25,160 shares in the company, valued at $1,383,800. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 371,571 shares of company stock worth $22,617,425. 4.50% of the stock is currently owned by corporate insiders.
Several equities analysts recently commented on the company. BTIG Research set a $70.00 price target on Integra Lifesciences and gave the stock a “buy” rating in a research report on Wednesday, July 24th. BidaskClub lowered Integra Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 28th. Oppenheimer boosted their price target on Integra Lifesciences from $65.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Wells Fargo & Co boosted their price target on Integra Lifesciences from $55.00 to $68.00 and gave the stock a “market perform” rating in a research report on Thursday, July 25th. Finally, JMP Securities boosted their price target on Integra Lifesciences to $75.00 in a research report on Thursday, July 25th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $62.67.
Shares of IART traded down $0.47 during trading on Friday, reaching $61.40. The company’s stock had a trading volume of 367,778 shares, compared to its average volume of 497,815. The company has a fifty day moving average of $61.45 and a two-hundred day moving average of $55.12. Integra Lifesciences Holdings Corp has a twelve month low of $42.14 and a twelve month high of $66.41. The company has a market cap of $5.29 billion, a price-to-earnings ratio of 25.37, a P/E/G ratio of 1.94 and a beta of 1.10. The company has a quick ratio of 1.82, a current ratio of 2.76 and a debt-to-equity ratio of 0.99.
Integra Lifesciences (NASDAQ:IART) last announced its earnings results on Wednesday, July 24th. The life sciences company reported $0.73 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.08. Integra Lifesciences had a return on equity of 16.30% and a net margin of 6.76%. The company had revenue of $383.60 million for the quarter, compared to analyst estimates of $373.29 million. During the same period in the prior year, the company posted $0.60 EPS. Integra Lifesciences’s quarterly revenue was up 4.8% on a year-over-year basis. As a group, equities analysts forecast that Integra Lifesciences Holdings Corp will post 2.73 EPS for the current fiscal year.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Further Reading: Mutual Funds
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.